The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 14, 2023

Filed:

Jan. 10, 2017
Applicant:

Eli Lilly and Company, Indianapolis, IN (US);

Inventors:

John Brian Mumm, Los Altos Hills, CA (US);

Ivan Ho Chan, Millbrae, CA (US);

Scott McCauley, Brisbane, CA (US);

Scott Ogg, San Francisco, CA (US);

Martin Oft, Palo Alto, CA (US);

Assignee:

Eli Lilly and Company, Indianapolis, IN (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 5/00 (2006.01); A61K 39/00 (2006.01); C12Q 1/6881 (2018.01); A61K 38/20 (2006.01); A61K 39/39 (2006.01); A61K 47/60 (2017.01); A61P 35/00 (2006.01); A61K 35/17 (2015.01); A61K 45/06 (2006.01); C07K 14/725 (2006.01); C12N 5/0783 (2010.01);
U.S. Cl.
CPC ...
C12Q 1/6881 (2013.01); A61K 35/17 (2013.01); A61K 38/2066 (2013.01); A61K 39/0011 (2013.01); A61K 39/39 (2013.01); A61K 45/06 (2013.01); A61K 47/60 (2017.08); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C12N 5/0637 (2013.01); A61K 2039/55527 (2013.01); A61K 2039/572 (2013.01); C12N 2501/998 (2013.01); C12Q 2600/136 (2013.01);
Abstract

The present disclosure provides methods and compositions relating to isolated CD8+ T cells expressing a disease antigen-specific T cell receptor, as well as nucleic acids encoding the Vα and Vβ polypeptide pairs of T cell receptors (TCRs) of such disease antigen-specific T cells. Such disease antigen-specific CD8+ T cells are obtainable from the periphery (e.g., blood) of a subject having a disease amenable to treatment with an IL-10 agent. The present disclosure also contemplates therapeutic methods and compositions relating to administration of isolated disease antigen-specific CD8+ T cells to a subject, as well as therapeutic methods and compositions relating to CD8+ T cells genetically modified to express a disease antigen-specific TCR and/or chimeric antigen receptor.


Find Patent Forward Citations

Loading…